Jump to content

PureTech Health

From Simple English Wikipedia, the free encyclopedia
PureTech Health
Company typePublic
HeadquartersBoston, United States
Key people
Christopher Viehbacher (Chairman)
Daphne Zohar (CEO)
RevenueDecrease $15.6 million (2022)[1]
Decrease $(197.8) million (2022)[1]
Increase $(37.4) million (2022)[1]

PureTech Health is a biotech company listed on the London Stock Exchange and included in the FTSE 250 Index. It was founded in 2005 by Daphne Zohar.[2] PureTech Health develops medicines to treat serious diseases. It has subsidiary companies focused on various therapeutic areas, including neuropsychiatric disorders, weight management, cognitive disorders, autoimmune diseases, and inflammatory diseases.[3] They also have their own pipeline of therapeutics in immunology, lymphatics, and oncology.[4]

References[change | change source]

  1. 1.0 1.1 1.2 "Annual Results 2022". PureTech Health. Retrieved 28 April 2023.
  2. "PureTech's long view on biopharma". Boston Globe. 26 August 2015. Archived from the original on 16 August 2019. Retrieved 16 August 2019.
  3. "PureTech Health affiliate Vedanta Biosciences awarded $5.8m grant". Sharecast. 5 December 2019. Archived from the original on 14 December 2019. Retrieved 14 December 2019.
  4. "PureTech Licenses Glyph Lymphatic Technology". FT. 29 August 2017. Archived from the original on 15 January 2020. Retrieved 14 December 2019.